Welcome to our dedicated page for Creative Med Technology Hldgs SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Creative Medical Technology Holdings� latest 10-K to track cash runway or decipher which stem-cell program moved into Phase II can feel like untangling lab notes. The company’s biotech focus means every SEC filing is packed with clinical-trial data, patent updates and licensing terms that investors can’t afford to miss. That complexity is the problem.
Stock Titan provides the solution. Our AI-powered summaries turn hundreds of pages into concise insights, so understanding Creative Medical Technology Holdings SEC documents with AI takes minutes. Receive real-time alerts the moment a Creative Medical Technology Holdings Form 4 insider transactions real-time notice hits EDGAR, examine a Creative Medical Technology Holdings quarterly earnings report 10-Q filing for R&D expense trends, or see a Creative Medical Technology Holdings 8-K material events explained in plain English—without searching line by line.
Need to compare executive pay against clinical milestones? The Creative Medical Technology Holdings proxy statement executive compensation section is mapped to key performance indicators. Tracking insider sentiment is simple thanks to dedicated pages for Creative Medical Technology Holdings insider trading Form 4 transactions and Creative Medical Technology Holdings executive stock transactions Form 4. For bigger-picture context, our platform delivers a Creative Medical Technology Holdings annual report 10-K simplified walkthrough and an actionable Creative Medical Technology Holdings earnings report filing analysis each quarter.
With AI-powered summaries, expert commentary and comprehensive coverage of every filing type—from 10-Q to 8-K—Stock Titan lets you focus on what matters: assessing pipeline progress, monitoring capital needs and making informed decisions faster than ever.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 135,531 shares of Creative Medical Technology Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund, and Mr. Boyd, as managing member, is reported with the same shared voting and dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The Master Fund is identified as the direct holder and retains the right to receive dividends or sale proceeds.
Creative Medical Technology Holdings, Inc. reported cash and short-term investments of $6,544,120 and total assets of $7,105,228 at June 30, 2025, with positive working capital of approximately $6,355,063 and stockholders' equity of $6,827,584. The company remains unprofitable, recording a six-month net loss of $2,871,400 versus $2,599,272 a year earlier.
Commercial revenue was minimal: $0 for the quarter and $3,000 for the six months, down from $8,000 a year ago. Operating loss for the six months was $2,923,998. Research and development expense for the six months totaled $1,244,565 while selling, general and administrative expense was $1,619,914. Basic net loss per share for six months was $(1.26) on a weighted average of 2,282,290 shares.
The company strengthened liquidity through warrant exercises and related financings, generating approximately $3.7 million of net proceeds during the period and reporting 4,147,478 warrants outstanding at June 30, 2025. Clinical programs show material progress: an independent Data Safety Monitoring Board completed a safety review and recommended continuation of the CELZ-201 ADAPT trial after initial cohorts, and the company completed dosing of the second cohort (20 patients total) in Q2 2025.
FAQ
What is the current stock price of Creative Med Technology Hldgs (CELZ)?
What is the market cap of Creative Med Technology Hldgs (CELZ)?
